Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas, Osaka University Join Hands in Cell Therapy Research
February 3, 2015
- Sumitomo Dainippon Revving Up “Post-Latuda” Development Drive
February 3, 2015
- 2014 Was “Difficult Year” as Generics Gained Ground: Kyowa Kirin Pres.
February 3, 2015
- Takeda Terminates Development of Combined Quadruple Vaccine
February 3, 2015
- Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015
- Drug Price Cuts, Generic Erosion Weigh Kyowa Kirin Earnings
February 2, 2015
- Over 500 Daiichi Sankyo Employees Take Voluntary Redundancy
February 2, 2015
- Astellas Licenses Pollinosis Vaccine from Immunomic Therapeutics
February 2, 2015
- Kyowa Hakko Bio Names Mr Kotani as New President
February 2, 2015
- Chugai to Set Up Global Organization to Bolster Early Clinical Development Functions
January 30, 2015
- Abilify Rakes in US Sales of Nearly US$5 Billion in 2014: Otsuka
January 29, 2015
- Chugai Sales Grow 8.8% Thanks to Increasing Actemra Exports
January 29, 2015
- Astellas, Takeda to Lead Pack in FY2018 Japan Pharma Market: Citi Analyst
January 29, 2015
- Otsuka Establishes Marketing Base in Australia
January 29, 2015
- Astellas to Transfer Marketing Rights for 3 APIs to OrphanPacific
January 28, 2015
- PD-1, PD-L1 Inhibitors Could Carve Out 750 Billion Yen Market in Japan: Citi Analyst
January 28, 2015
- Takeda Launches Fomepizole
January 28, 2015
- Galderma Terminates Comarketing Agreement with Sato Pharmaceutical for Pekiron Cream
January 28, 2015
- Torii Files NDA for Sublingual Tablet for Mite Allergic Rhinitis
January 28, 2015
- Santen’s Dry Eye Treatment Receives Positive Opinion from CHMP
January 28, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…